Alerta

AN AUTOMATED PORTABLE WIRELESS DIABETIC FOOT RISK PROFILER DEVICE AND SYSTEM

Resumen de: WO2026110048A1

The present invention provides an automated portable wireless diabetic foot risk profiler system. The system comprises portable devices include a first portable device (103) configured to perform neuropathy assessment by producing a vibration and tactile sensation and detecting the response of a patient, and a second portable device (104) configured to perform vascular assessment by measuring blood pressure and detecting pulse wave pattern of the patient. The central control panel (102) perform real-time data acquisition and processing of a data including response of a patient to said vibration and tactile sensation along with the blood pressure measurement and pulse wave patterns. The remote response button unit (105) is for getting response directly from the patient to capture the value of tactile and vibration sensation in real time. The remote server (101) is for remote synchronization of data and remote data management.

HYDROGEL FOR BODY CAVITY INJURY TREATMENT AND BODY CAVITY INJURY TREATMENT KIT

Resumen de: US20260144811A1

0000 A hydrogel for treatment of body cavity injury is derived from a chitosan derivative in which an aldonic acid is bound to an amino group of a glucosamine unit of chitosan by dehydration condensation. The hydrogel for treatment of body cavity injury has a granular shape. The hydrogel is injected into a body cavity using an injection device, and used for wound treatment of the body cavity. A kit for treatment of body cavity injury includes: an injection device; a tube to be connected to the injection device; and a hydrogel for treatment of body cavity injury, filled in the injection device and having a granular shape; wherein the hydrogel for treatment of body cavity injury is derived from a chitosan derivative in which an aldonic acid is bound to an amino group of a glucosamine unit of chitosan by dehydration condensation.

BLOOD GLUCOSE MANAGEMENT SYSTEM FOR ESTABLISHING WIRELESS COMMUNICATION CONNECTION ON BASIS OF SIGNAL STRENGTH

Resumen de: WO2026107790A1

Disclosed in the present invention is a blood glucose management system for establishing a wireless communication connection on the basis of signal strength. A signal strength threshold is preset in the blood glucose management system. During a period when a monitoring module and/or an infusion module is powered on and sends a broadcast signal, a program module searches for a nearby broadcast signal and identifies the signal strength of the broadcast signal. When the signal strength of the broadcast signal is not less than the preset signal strength threshold, the program module can establish a wireless communication connection with the monitoring module and/or the infusion module that sends the broadcast signal, without the need to input a device identifier of the monitoring module and/or the infusion module. Moreover, since the broadcast signal identified by the program module is sufficiently strong, it means that the program module is in proximity to the monitoring module and/or the infusion module that sends the broadcast signal, thereby ensuring the reliability of the program module establishing a wireless communication connection with a patient's own monitoring module and/or infusion module.

USE OF URIDINE DIPHOSPHATE GLUCOSE IN TREATMENT OF ABNORMAL LIVER GLUCOLIPID METABOLISM

Resumen de: EP4748379A1

0001 A use of uridine diphosphate glucose (UDPG) in treatment of abnormal liver glucolipid metabolism. Specifically, a use of UDPG or a pharmaceutical composition comprising same in the preparation of a drug for preventing and/or treating abnormal liver glucolipid metabolism, wherein the abnormal liver glucolipid metabolism is preferably nonalcoholic fatty liver disease, dyslipidemia and related cardiovascular diseases. Treatment using UDPG can reduce lipid synthesis and lipid synthesis related gene expression in the liver.

System and method for determining biological age, aging rate, and life expectancy trend from continuously measured blood glucose.

Resumen de: SK3002025U1

System for determining biological age and life expectancy trend based on continuously measured glycemia processes CGM data using the internal AGE Index / BVI algorithm, which determines biological age and the trend of its changes. Increased glycemia is associated with accelerated biological aging. The system provides indicative information about biological age, its trend and the risk of premature mortality.

PHARMACEUTICAL FORMULATIONS

Resumen de: EP4748398A2

0001 Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.

CONTINUOUS BLOOD GLUCOSE MONITORING

Resumen de: EP4749425A2

0001 A system, a method, and a computer program product for providing wearable continuous blood glucose monitoring. In some embodiments, there is provided a method that includes receiving, at a smartwatch, an alert representative of a glucose state of a host-patient coupled to a glucose sensor; detecting, at the smartwatch, a predetermined action indicative of a request to generate a glance view providing an indication of the glucose state of the host-patient; and presenting, at the smartwatch and in response to the detecting, the glance view providing the indication of the glucose state of the host-patient.

BODY ATTACHABLE UNIT FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT

Resumen de: EP4748310A2

The present invention relates to a body attachment unit for continuous blood glucose monitoring, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and activation can occur in a stabilized state, and thereby allowing more accurate blood glucose monitoring.

MEASUREMENT METHOD, SYSTEM, AND RELATED APPARATUS

Resumen de: EP4748312A1

This application discloses a measurement method, a system, and a related apparatus. The method is applied to a first electronic device, the first electronic device includes a first electrode group and a second electrode group, and a distance between the first electrode group and the second electrode group is greater than a first distance. When the first electrode group and the second electrode group are implanted into a subcutaneous tissue, the method includes: determining a first physiological parameter by using the first electrode group; and determining an electrocardiography signal by using the first electrode group and the second electrode group. In this way, the first electronic device may obtain an electrocardiography signal of a user anytime and anywhere, and may further measure one or more other physiological parameters (for example, blood glucose, blood ketone, blood lactic acid, and uric acid) of the user at the same time, to improve health monitoring efficiency.

ADVANCED CONTINUOUS ANALYTE MONITORING SYSTEM

Resumen de: EP4749952A2

0001 The present invention relates generally to systems and methods for processing, transmitting, and displaying data received from continuous analyte sensor 10, such as a glucose sensor. In some embodiments, the continuous analyte sensor system 8 comprises a sensor electronics module 12 that includes power saving features. One feature includes a low power measurement circuit that can be switched between a measurement mode and a low power mode, in which charging circuitry continues to apply power to electrodes of a sensor during the low power mode. In addition, the sensor electronics module can be switched between in a low power storage mode higher power operational mode via a switch. The switch can include a reed switch or optical switch, for example. A validation routine can also be implemented to ensure an interrupt signal sent from the switch is valid. The continuous analyte sensor 10 can be physically connected to a sensor electronics module 12, which is in direct wireless communication with a plurality of different display devices 14, 16, 18, and/or 20.

MEASUREMENT DEVICE

Resumen de: EP4748307A1

The present technology relates to a measurement apparatus capable of improving measurement accuracy.The measurement apparatus includes: a circuit portion that is arranged on one surface of a sensor substrate and measures an S parameter; and a sensor electrode that is arranged on the other surface of the sensor substrate and irradiates a measurement target with a signal for measuring the S parameter output from the circuit portion, in which a distance between the circuit portion and the sensor electrode is equal to or less than a predetermined distance in plan view, and a terminal that outputs the signal of the circuit portion is directly connected to the sensor substrate. The present technology can be applied to a glucose sensing system.

INFUSION PUMP SYSTEM WITH SIMPLIFIED FALLBACK CLOSED LOOP ALGORITHM

Resumen de: WO2026106887A1

Methods and systems are configured for maintaining closed loop therapy in circumstances where a phone or other user device providing therapy commands to the pump according to a closed loop therapy algorithm becomes disconnected from the pump. A fallback or backup closed loop algorithm can be stored on the pump that may be a simplified version of the closed loop algorithm operated on the phone having lower memory and computational requirements such that it can be operated on the pump. The fallback algorithm may also require less battery power to be operated. If the pump detects that the connection with the phone has been lost, the pump can establish communications with the CGM to receive the glucose levels (if not already connected). The pump can then activate the fallback close loop algorithm stored on the pump and make therapy determinations based on the CGM data according to the fallback closed loop algorithm.

MEAL BOLUS SUBCATEGORIES IN MODEL BASED INSULIN THERAPY

Resumen de: US20260137310A1

0000 Disclosed are examples that include receiving information related to ingestion of a meal. The information may include a coarse indication of a size of the meal, a relative time of ingestion of the meal, and a general composition indication of the meal. A blood glucose measurement value received within a predetermined time range of a relative time of ingestion of the meal may be identified. Settings for a delay and an extend parameter and a delivery constraint may be determined. A meal model may be modified using the determined settings for the delay parameter, the extend parameter, and the delivery constraint. The modified meal model may be used to determine a dose of insulin to be delivered in response to the received information. An instruction indicates a determined dose of insulin to be delivered may be output for delivery to a drug delivery device.

SPHEROID CRYOPRESERVATION

Resumen de: WO2026107395A1

The disclosure relates to a cryopreservation medium comprising a diol, sugar, or both a diol and sugar. The disclosure also provides a use of the cryopreservation medium to cryopreserve a cell, a method of preparing a cell for preservation, and a method of cryopreserving a cell.

CONTINUOUS GLUCOSE MONITORING DEVICE

Resumen de: AU2023200010A1

The present disclosure relates to a continuous glucose monitoring device, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work for a user in attaching the body attachment unit to a body, and allowing attachment of the body attachment unit to the body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, the continuous glucose monitoring device is activated by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and the continuous glucose monitoring device can be activated in a stabilized state, and thereby can monitor blood glucose more accurately.

METHOD TO DETERMINE INSULIN RESISTANCE FROM CONTINUOUS GLUCOSE MONITORING (CGM) FOR PRE-DIABETIC CONDITIONS

Resumen de: US20260137353A1

Methods of predicting insulin resistance in a subject are provided. The methods include measuring interstitial fluid glucose in the subject over a period of time to obtain a plurality of glucose values (G(tn)); fitting the measured plurality of glucose values (G(tn)) to a glucose-insulin response model to calculate a plurality of subject-specific parameters, the glucose-insulin response model comprising a modified Lotka-Volterra system of equations for the glucose-insulin response pair (G(t), I(t)); and comparing at least one of the calculated subject-specific parameters to a set threshold value to predict insulin resistance in the subject. Systems for predicting insulin resistance in a subject are also provided. The systems include a continuous glucose monitoring (CGM) sensor and a computation device.

COMPENSATION METHOD AND DEVICE FOR CONTINUOUS GLUCOSE MONITOR

Resumen de: US20260137313A1

0000 A compensation method for a continuous glucose monitor includes: acquiring a glucose value of a user continuously; determining a user type and a glucose trend type according to the glucose value, where the user type includes at least a first user type and a second user type; determining, based on the glucose value, whether a compensation start condition is satisfied; starting a compensation algorithm if the compensation start condition is satisfied; determining a compensation formula based on the glucose value and the glucose trend type; and obtaining, based on the glucose value and the compensation formula, a compensated glucose value until a compensation stop condition is satisfied.

MOF-BASED GLUCOSE DETECTION SYSTEM, SENSOR FOR DETECTING GLUCOSE CONCENTRATION IN SALIVA, AND NON-INVASIVE ORAL GLUCOSE METER

Resumen de: WO2026103909A1

A method for preparing an MOF-based glucose detection system, wherein a Zeolitic Imidazolate Framework (ZIF) is used as a metal-organic framework, and glucose oxidase (GOx) is loaded in the zeolitic imidazolate framework. The preparation method comprises the following steps: S1: adding water to a reaction flask in advance, and then sequentially adding a metal ion, an enzyme and an organic ligand in a molar ratio of 100-1500:1-10:1-150, and 0.1-0.5% (by weight) of ammonia water to the reaction flask, S2: mixing and reacting same at room temperature for more than 6 hours, and S3: after centrifugation by means of a centrifuge, removing the supernatant to obtain a solid precipitate of the Gox-MOF material loaded with glucose oxidase. A sensor for detecting trace glucose concentration in saliva, and an oral glucose meter comprising the sensor.

INTEGRATED CGM AND INSULIN PUMP SYSTEM

Resumen de: WO2026106928A1

Ambulatory infusion pump systems can integrate a CGM sensor with an ambulatory infusion pump via a pump holder or tray that releasably holds the pump and is configured to be worn by a user. By combining the CGM and insulin pump into one integrated system, a more aesthetically pleasing, convenient and reliable system is provided. Diabetes management is simplified by consolidating two essential devices into one.

MEASUREMENT OF GLUCOSE NEAR AN INSULIN DELIVERY CATHETER BY MINIMIZING THE ADVERSE EFFECTS OF INSULIN PRESERVATIVES: ALTERNATIVE LIGANDS AND REDOX MEDIATOR METALS

Resumen de: US20260137312A1

A device for delivery of an insulin or insulin analog formulation and measurement of subcutaneous glucose concentration may comprise a hollow tube, and an amperometric glucose sensor located proximal to a distal end of the hollow tube. The amperometric glucose sensor may comprise a redox mediator and an enzyme comprising glucose oxidase or glucose dehydrogenase. An applied bias potential may allow an electrode layer of the amperometric glucose sensor to undergo substantially no electropolymerization of an excipient of the insulin or insulin analog formulation during continuous operation of amperometric glucose sensor. A sensitivity of the amperometric glucose sensor to the subcutaneous glucose concentration may be maintained in presence of the insulin or insulin analog formulation.

SENSOR APPLICATOR ASSEMBLY FOR CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: US2020178899A1

The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.

Implantable continuous glucose monitor device

Resumen de: US12629065B1

0000 A continuous glucose monitor (CGM) sensor includes a glucose oxidation electrode and a counter electrode, and does not include a glucose-specific enzyme. The glucose oxidation electrode includes a nanoporous layer comprising metal nanoparticles. The CGM sensor generates an electrical signal indicative glucose oxidation in a liquid containing glucose, which has a correlation with an effective surface area of the metal nanoparticles in the nanoporous layer. When the CGM sensor is implanted in a subject's body, an AC voltage is applied between the glucose oxidation electrode and the counter electrode, and impedance is obtained. A glucose level for the subject is determined using the impedance without use of information or data related to glucose sensitivity of a sensor or sensors over use or time.

Integrated glucose monitoring system

Nº publicación: US12629058B1 19/05/2026

Solicitante:

TULA HEALTH INC [US]
Tula Health, Inc.

Resumen de: US12629058B1

An integrated glucose monitoring system may include a glucometer and an electronic temperature sensor. The glucometer may be configured to attach to a mobile device. The glucometer may include a test strip aperture, measurement electronics, an electronics port, and/or a cooling vent configured to vent air across the measurement electronics. The temperature sensor may be physically coupled to the glucometer. The temperature sensor may be exposed from the glucometer to an ambient environment approximate the glucometer. The temperature sensor may be electronically coupled to the measurement electronics. The measurement electronics may be configured to adjust a blood glucose reading based on an ambient temperature reading taken by the electronic temperature sensor approximately concurrently with the blood glucose reading.